Barrington Research Raises LeMaitre Vascular (NASDAQ:LMAT) Price Target to $120.00

Key Points

• Barrington Research raised its price target on LeMaitre Vascular to $120 (from $105) and kept an "outperform" rating, while other analysts have also bumped targets (Citizens JMP to $127), leaving a consensus rating of Moderate Buy and a consensus target of $112.60.
• LeMaitre beat Q1 estimates with $0.68 EPS vs. $0.66 and revenue up 11.1% YoY, and management raised guidance to Q2 $0.79–$0.84 and FY26 $2.93–$3.08, signaling confidence in near-term growth.
• Significant insider selling occurred recently (CEO sold 55,930 shares for ~$6.03M; insiders sold 215,438 shares over 90 days), even as institutional ownership remains high at 84.64%.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) had its target price lifted by investment analysts at Barrington Research from $105.00 to $120.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The brokerage currently has an "outperform" rating on the medical instruments supplier's stock. Barrington Research's price target would indicate a potential upside of 8.87% from the company's previous close.

Several other equities analysts have also commented on the stock. Citizens Jmp upped their price target on shares of LeMaitre Vascular from $118.00 to $127.00 and gave the stock a "market outperform" rating in a research report on Wednesday. Zacks Research raised shares of LeMaitre Vascular from a "hold" rating to a "strong-buy" rating in a research report on Monday, April 13th. Freedom Capital raised shares of LeMaitre Vascular to a "hold" rating in a research report on Tuesday, March 31st. Roth Mkm reissued a "buy" rating and issued a $117.00 price objective (up from $108.00) on shares of LeMaitre Vascular in a research report on Thursday, February 26th. Finally, Wall Street Zen raised shares of LeMaitre Vascular from a "hold" rating to a "buy" rating in a research report on Saturday, February 21st. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and three have assigned a Hold rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $112.60.

LeMaitre Vascular Trading Down 1.6%

LMAT stock traded down $1.78 on Wednesday, hitting $110.22. 316,977 shares of the company were exchanged, compared to its average volume of 205,458. LeMaitre Vascular has a twelve month low of $78.35 and a twelve month high of $118.01. The company has a debt-to-equity ratio of 0.43, a current ratio of 12.89 and a quick ratio of 10.95. The business's fifty day moving average is $109.66 and its two-hundred day moving average is $94.33. The stock has a market capitalization of $2.52 billion, a price-to-earnings ratio of 43.91, a price-to-earnings-growth ratio of 3.21 and a beta of 0.60.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last issued its quarterly earnings results on Tuesday, May 5th. The medical instruments supplier reported $0.68 EPS for the quarter, topping the consensus estimate of $0.66 by $0.02. LeMaitre Vascular had a net margin of 23.13% and a return on equity of 14.72%. The firm had revenue of $66.55 million during the quarter, compared to analyst estimates of $66.67 million. During the same quarter in the prior year, the business posted $0.48 earnings per share. LeMaitre Vascular's revenue for the quarter was up 11.1% compared to the same quarter last year. LeMaitre Vascular has set its FY 2026 guidance at 2.930-3.080 EPS and its Q2 2026 guidance at 0.790-0.840 EPS. As a group, research analysts forecast that LeMaitre Vascular will post 2.89 earnings per share for the current year.

Insider Transactions at LeMaitre Vascular

In related news, insider Trent G. Kamke sold 1,044 shares of the firm's stock in a transaction on Friday, February 27th. The shares were sold at an average price of $110.29, for a total transaction of $115,142.76. Following the completion of the sale, the insider directly owned 6,677 shares of the company's stock, valued at approximately $736,406.33. This trade represents a 13.52% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO George W. Lemaitre sold 55,930 shares of the firm's stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $107.81, for a total transaction of $6,029,813.30. Following the sale, the chief executive officer directly owned 1,476,500 shares of the company's stock, valued at approximately $159,181,465. The trade was a 3.65% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 215,438 shares of company stock valued at $23,062,911 over the last 90 days. Corporate insiders own 7.40% of the company's stock.

Institutional Investors Weigh In On LeMaitre Vascular

A number of large investors have recently added to or reduced their stakes in LMAT. Royal Bank of Canada grew its holdings in LeMaitre Vascular by 1.5% during the 1st quarter. Royal Bank of Canada now owns 114,176 shares of the medical instruments supplier's stock valued at $9,579,000 after purchasing an additional 1,735 shares in the last quarter. AQR Capital Management LLC grew its holdings in LeMaitre Vascular by 36.4% during the 1st quarter. AQR Capital Management LLC now owns 27,878 shares of the medical instruments supplier's stock valued at $2,339,000 after purchasing an additional 7,445 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in LeMaitre Vascular by 4.7% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,078 shares of the medical instruments supplier's stock valued at $1,013,000 after purchasing an additional 539 shares in the last quarter. Millennium Management LLC grew its holdings in LeMaitre Vascular by 119.8% during the 1st quarter. Millennium Management LLC now owns 211,222 shares of the medical instruments supplier's stock valued at $17,722,000 after purchasing an additional 115,141 shares in the last quarter. Finally, Goldman Sachs Group Inc. grew its holdings in LeMaitre Vascular by 27.0% during the 1st quarter. Goldman Sachs Group Inc. now owns 262,445 shares of the medical instruments supplier's stock valued at $22,019,000 after purchasing an additional 55,804 shares in the last quarter. 84.64% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting LeMaitre Vascular

Here are the key news stories impacting LeMaitre Vascular this week:

• Positive Sentiment: Q1 EPS beat and year-over-year growth — LMAT reported $0.68 EPS vs. $0.66 consensus and revenue up 11.1% YoY, showing solid margin performance. This supports the stock’s premium multiple. Article Title
• Positive Sentiment: Management raised guidance — LMAT issued Q2 EPS guidance of $0.79–$0.84 (above Street) and FY26 EPS guidance of $2.93–$3.08 (slightly above consensus), indicating confidence in near-term growth. This is a primary bullish catalyst. Article Title
• Positive Sentiment: Analyst price-target upgrade from Citizens JMP — Citizens JMP raised its target to $127 and moved to “market outperform,” signaling a ~15% upside versus current levels and offering support for the share price. Article Title
• Neutral Sentiment: Quarterly dividend announced — Board declared a $0.25 quarterly dividend (ex-div May 21), a modest yield that may appeal to income-focused investors but is unlikely to materially move the stock. Article Title
• Neutral Sentiment: Earnings call transcript available — Investors can review management’s commentary for color on procedure volumes, margin drivers, and cadence for the rest of 2026. Article Title
• Negative Sentiment: Wells Fargo keeps “equal weight” and trims target — Wells Fargo raised its target to $104 but maintains an equal-weight stance, implying downside versus current levels and signaling some analyst caution that could pressure the stock. Article Title

About LeMaitre Vascular

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company's offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre's product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.